- Research Tools
- Rose Freel
Baculoviruses have been used for decades to produce proteins in insect cell hosts. Current systems for generating recombinant baculovirus have several shortcomings which prevent their easy use in high-throughput applications.
Researchers within the Frederick National Laboratory for Cancer Research have developed an improved system called Bac-2-the-future, or B2F, to quickly and efficiently generate recombinant baculoviruses which produce recombinant proteins. In the new system, the baculovirus transfer vector, transposition helper plasmid, and E. coli strain carrying the bacmid DNA were modified to eliminate the need for screening positive clones and improve the efficiency of baculovirus production. Taken together, these improvements permit facile high-throughput recombinant baculovirus production at reduced cost and improved speed over the currently available systems. The new transfer vectors and E. coli strains of the B2F system are available for licensing.
- High-throughput protein production
- Generation of virus-like particles in insect cells
- Elimination of background plasmid DNA during recombinant baculovirus production
- Elimination of nonproductive transposition events leading to false positives
- Lower cost production of baculovirus
- Increased speed of baculovirus production (allowing high-throughput production with limited screening)
- Higher efficiency cloning of baculovirus constructs
- Prototype
Mehalko JL, et al. Engineering the transposition-based baculovirus expression vector system for higher efficiency protein production from insect cells. [PMID 27616621]
- Research Material: NIH will not pursue patent prosecution for this technology
- E-164-2011
- Cancer/Neoplasm
- Infectious Diseases
- Immune System and Inflammation
- Eye and Ear, Nose & Throat
- Hormonal Systems, Endocrine, and Metabolic Diseases
- Cardiovascular Systems
- Gastrointestinal
- Kidney and the Genitourinary
- Musculoskeletal
- Reproductive
- Skin and Subcutaneous Tissue
- Metabolic Disease